Legend Biotech Corporatio... (LEGN)
Legend Biotech Statistics
Share Statistics
Legend Biotech has 91.73M shares outstanding. The number of shares has increased by 0.85% in one year.
| Shares Outstanding | 91.73M |
| Shares Change (YoY) | 0.85% |
| Shares Change (QoQ) | 0.15% |
| Owned by Institutions (%) | 54.33% |
| Shares Floating | 90.47M |
| Failed to Deliver (FTD) Shares | 66 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 13.11M, so 7.14% of the outstanding shares have been sold short.
| Short Interest | 13.11M |
| Short % of Shares Out | 7.14% |
| Short % of Float | 7.2% |
| Short Ratio (days to cover) | 9.35 |
Valuation Ratios
The PE ratio is -16.81 and the forward PE ratio is -48.09. Legend Biotech's PEG ratio is 0.25.
| PE Ratio | -16.81 |
| Forward PE | -48.09 |
| PS Ratio | 4.74 |
| Forward PS | 1.2 |
| PB Ratio | 2.86 |
| P/FCF Ratio | -18.81 |
| PEG Ratio | 0.25 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Legend Biotech Corporation.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.34.
| Current Ratio | 4.62 |
| Quick Ratio | 4.54 |
| Debt / Equity | 0.34 |
| Total Debt / Capitalization | 25.2 |
| Cash Flow / Debt | -0.41 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.17% and return on capital (ROIC) is 0%.
| Return on Equity (ROE) | -0.17% |
| Return on Assets (ROA) | -0.11% |
| Return on Capital (ROIC) | 0% |
| Revenue Per Employee | $241,246.54 |
| Profits Per Employee | $-68,086.92 |
| Employee Count | 2,600 |
| Asset Turnover | 0.38 |
| Inventory Turnover | 9.81 |
Taxes
| Income Tax | 18.89M |
| Effective Tax Rate | -0.12 |
Stock Price Statistics
The stock price has increased by -35.16% in the last 52 weeks. The beta is 0.2, so Legend Biotech's price volatility has been higher than the market average.
| Beta | 0.2 |
| 52-Week Price Change | -35.16% |
| 50-Day Moving Average | 35.98 |
| 200-Day Moving Average | 43.95 |
| Relative Strength Index (RSI) | 54.82 |
| Average Volume (20 Days) | 1.23M |
Income Statement
In the last 12 months, Legend Biotech had revenue of 627.24M and earned -177.03M in profits. Earnings per share was -0.97.
| Revenue | 627.24M |
| Gross Profit | 392.66M |
| Operating Income | 0 |
| Net Income | -177.03M |
| EBITDA | -113.16M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.97 |
Balance Sheet
The company has 286.75M in cash and 350.6M in debt, giving a net cash position of -63.85M.
| Cash & Cash Equivalents | 286.75M |
| Total Debt | 350.6M |
| Net Cash | -63.85M |
| Retained Earnings | -1.66B |
| Total Assets | 1.67B |
| Working Capital | 1.01B |
Cash Flow
In the last 12 months, operating cash flow was -144.03M and capital expenditures -14.11M, giving a free cash flow of -158.14M.
| Operating Cash Flow | -144.03M |
| Capital Expenditures | -14.11M |
| Free Cash Flow | -158.14M |
| FCF Per Share | -0.86 |
Margins
Gross margin is 62.6%, with operating and profit margins of 0% and -28.22%.
| Gross Margin | 62.6% |
| Operating Margin | n/a |
| Pretax Margin | -25.21% |
| Profit Margin | -28.22% |
| EBITDA Margin | -18.04% |
| EBIT Margin | n/a |
| FCF Margin | -25.21% |
Dividends & Yields
LEGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2.57% |
| FCF Yield | -4.57% |
Analyst Forecast
The average price target for LEGN is $80, which is 111.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $80 |
| Price Target Difference | 111.9% |
| Analyst Consensus | Buy |
| Analyst Count | 12 |
Scores
| Altman Z-Score | 2.75 |
| Piotroski F-Score | 3 |